A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)

被引：0
|
作者：
Kittai, Adam
Skarbnik, Alan
Miranda, Miguel
Yong, Alan S. M.
Roos, Jack
Hettle, Robert
Palazuelos-Munoz, Sarah
Shetty, Vikram
Ghia, Paolo
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA
[2] Novant Hlth Canc Inst, Charlotte, NC USA
[3] AstraZeneca, Cambridge, England
[4] AstraZeneca, Wilmington, DE USA
[5] Univ Vita Salute San Raffaele, Milan, Italy
[6] IRCCS Osped San Raffaele, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7540
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)
    Staber, P.
    Kittai, A.
    Skarbnik, A.
    Miranda, M.
    Yong, A. S.
    Roos, J.
    Hettle, R.
    Palazuelos-Munoz, S.
    Shetty, V.
    Ghia, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 218 - 218
  • [2] Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): Matching-adjusted indirect comparison (MAIC)
    Thieblemont, Catherine
    Wang, Kaijun
    Keeping, Sam
    Zhang, Ina
    Yang, Keri
    Tang, Boxiong
    Mohseninejad, Leyla
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)
    Thieblemont, Catherine
    Wang, Kaijun
    Keeping, Sam
    Zhang, Ina
    Yang, Keri
    Tang, Boxiong
    Mohseninejad, Leyla
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
    Allan, John N.
    Kittai, Adam S.
    James, Dan
    Ridge, Helen
    Miranda, Miguel
    Yong, Alan
    Fam, Fady
    Roos, Jack
    Shetty, Vikram
    Davids, Matthew S.
    Skarbnik, Alan
    BLOOD, 2023, 142
  • [5] MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Telford, C.
    Kabadi, S.
    Abhyankar, S.
    Song, J.
    Signorovitch, J.
    Zhao, J.
    Yao, Z.
    VALUE IN HEALTH, 2019, 22 : S62 - S62
  • [6] Matching-adjusted indirect comparisons of efficacy and safety of Acalabrutinib versus Ibrutinib in treatment-naive chronic lymphocytic leukemia
    Dietrich, S.
    Davids, M.
    Telford, C.
    Abhyankar, S.
    Waweru, C.
    Ringshausen, I.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 72 - 72
  • [7] Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/ Refractory Mantle Cell Lymphoma
    Gaitonde, Priyanka
    Cai, Ling
    de Miranda, Paulo
    Roos, Jack
    Rule, Simon
    Wang, Michael L.
    BLOOD, 2022, 140 : 3646 - 3647
  • [8] Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Shadman, Mazyar
    Tedeschi, Alessandra
    Mohseninejad, Leyla
    Yang, Keri
    Lamanna, Nicole
    Xu, Sheng
    Cohen, Aileen Cleary
    Challagulla, Swetha
    Xue, Mei
    Williams, Rhys
    O'Brien, Susan M.
    Brown, Jennifer R.
    Tam, Constantine S.
    BLOOD, 2023, 142
  • [9] A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive chronic lymphocytic leukemia
    Kittai, Adam
    Allan, John
    James, Dan
    Bridge, Helen
    Miranda, Miguel
    Yong, Alan
    Fam, Fady
    Roos, Jack
    Shetty, Vikram
    Skarbnik, Alan
    Davids, Matthew
    LEUKEMIA & LYMPHOMA, 2023, 64 : S82 - S83
  • [10] Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
    Shadman, Mazyar
    Tedeschi, Alessandra
    Mohseninejad, Leyla
    Yang, Keri
    Lamanna, Nicole
    Xu, Sheng
    Cohen, Aileen
    Challagulla, Swetha
    Xue, Mei
    Williams, Rhys
    O'Brien, Susan M.
    Brown, Jennifer R.
    Tam, Constantine
    BLOOD CANCER JOURNAL, 2024, 14 (01):
12345